Aktis Oncology, Inc. (AKTS)
| Market Cap | 1.48B |
| Revenue (ttm) | 10.06M +576.5% |
| Net Income | -73.14M |
| EPS | -2.77 |
| Shares Out | 55.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 601,207 |
| Open | 26.30 |
| Previous Close | 25.98 |
| Day's Range | 25.47 - 26.89 |
| 52-Week Range | 14.72 - 34.19 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 34.81 (+30.42%) |
| Earnings Date | Aug 13, 2026 |
About AKTS
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225A... [Read more]
Financial Performance
In 2025, Aktis Oncology's revenue was $6.50 million, an increase of 336.92% compared to the previous year's $1.49 million. Losses were -$63.73 million, 44.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AKTS stock is "Strong Buy." The 12-month stock price target is $34.81, which is an increase of 30.42% from the latest price.
News
Wedbush starts Aktis Oncology at Outperform on radiopharma potential
Wedbush analyst David Nierengarten initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $35 price target The firm views Aktis as “compelling pure-play radiopharma story targeting ...
Aktis Oncology initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $35 price target
BMO starts Aktis at Outperform, says opportunities not captured in valuation
BMO Capital analyst David Lebowitz initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $37 price target The firm said its Outperform thesis is underpinned by the significant…
Aktis Oncology initiated with an Outperform at BMO Capital
BMO Capital analyst David Lebowitz initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $37 price target BMO rolled out coverage on nine biotechnology companies, saying each might...
Aktis Oncology reports Q2 revenue $3.38M, consensus $2.58M
“This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to support our clinical pipeline,” said Matthew Roden, President and Chief Executive ...
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted r...
Aktis Oncology Earnings release: Q2 2026
Aktis Oncology released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Aktis Oncology Quarterly report: Q2 2026
Aktis Oncology has published its Q2 2026 quarterly earnings report on August 13, 2026.
Aktis Oncology price target raised to $33 from $30 at JPMorgan
JPMorgan raised the firm’s price target on Aktis Oncology (AKTS) to $33 from $30 and keeps an Overweight rating on the shares. The firm upped the target after revisiting its…
Aktis Oncology initiated with a Strong Buy at Raymond James
Raymond James analyst Christopher Raymond initiated coverage of Aktis Oncology (AKTS) with a Strong Buy rating and $40 price target The firm thinks Aktis’ miniprotein-enabled radioligand therapy platf...
Aktis Oncology Transcript: Jefferies Global Healthcare Conference 2026
Aktis Oncology presented its strategy to expand radiopharmaceuticals to new patient groups using a proprietary mini-protein platform, with two lead assets in phase I-B trials targeting Nectin-4 and B7-H3. Robust early clinical data, strong financials, and a resilient supply chain support multi-indication development and upcoming milestones in 2027.
Aktis Oncology Slides: FY 2026
Aktis Oncology has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology (AKTS) to $35 from $33 and keeps a Buy rating on the shares after the company presented…
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmace...
Aktis Oncology Transcript: Status update
AKY-2519, a B7-H3-targeting radiopharmaceutical, demonstrated robust tumor uptake, high tumor-to-normal tissue dose ratios, and favorable safety in early studies. Experts highlighted its potential to address unmet needs in prostate and other solid tumors, with clinical trials underway in multiple indications.
Aktis Oncology Slides: Status update
Aktis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop...
Aktis Oncology Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing miniprotein radioconjugate therapies targeting Nectin-4 and B7-H3, supported by a robust discovery platform and strong financial position. Key clinical updates are expected in 2027, with ongoing collaborations and manufacturing investments to accelerate development and patient access.
Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M
Cash, cash equivalents and marketable securities were $538.5M as of March 31, compared to $226.8M as of December 31, 2025. “We continue to build momentum toward delivering a new class…
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop...
Aktis Oncology Earnings release: Q1 2026
Aktis Oncology released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Aktis Oncology Quarterly report: Q1 2026
Aktis Oncology has published its Q1 2026 quarterly earnings report on May 11, 2026.
Aktis Oncology to Present at the BofA Securities Health Care Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmace...
Aktis Oncology Transcript: Study update
AKY-2519, a B7-H3-targeted radioconjugate, has entered phase I-B trials for mCRPC, with a parallel basket trial in other solid tumors planned for late 2026. Imaging and dosimetry data will be presented at ASCO, and preliminary clinical data are expected in 2027.